Mobile

A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017359-92

A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objectives - To determine if afamelanotide can reduce the severity of PLE related pruritis.

Critère d'inclusion

  • Polymorphic light eruption (PLE)

Liens